If You Invested $10,000 in BioNTech in 2019, This Is How Much You Would Have Today
BioNTech (NASDAQ: BNTX) has almost become a household name. The German biotech company developed the Pfizer (NYSE: PFE) coronavirus vaccine. The two companies struck up a partnership and now are splitting vaccine revenue. This means billions of dollars in revenue for both. But it's a particularly big deal for BioNTech. That's because, only a year ago, the company didn't have any commercialized drugs or vaccines.
As you can probably guess, back then, BioNTech wasn't a stock market star. But, the company already was years into its work on mRNA technology. Today, BioNTech has more than two dozen candidates in its mRNA pipeline. And that doesn't happen overnight. Clearly, early believers in BioNTech have benefited since its partnership with Pfizer. Let's take a closer look to see exactly how much.
Image source: Getty Images.
Source Fool.com
